Intravitreal ziv-aflibercept for the treatment of choroidal neovascularisation associated with conditions other than age-related macular degeneration

Abstract

IVZ improves CMT in patients with CNV associated with causes other than AMD, but improvements in BCVA are modest.

Pilot study of ziv-aflibercept in myopic choroidal neovascularisation patients

“…This finding was quite similar to those from recent studies performed on ziv-aflibercept on a larger number of patients [ 32 , 33 ] that discussed the application of ziv-aflibercept in different retinal diseases and detected a reasonable safety profile for the drug comparable with those of other anti-VEGF agents. Moreover, Braimah et al [ 11 ] studied the efficacy of ziv-aflibercept on retinal diseases other than AMD, such as high myopia, macular telangiectasia, central serous chorioretinopathy, choroidal osteoma, choroiditis, Best’s disease and idiopathic macular degeneration, and reported a marked reduction in CMT and a moderate improvement in BCVA.…”

“…Patients were divided into two age groups to detect the influence of age on visual prognosis: group 1 included 12 patients ≥40 years old, and group 2 included the remaining eight patients, who were < 40 years old. Sample size calculation was based on the mean (SD) of BCVA pre- and post-treatment with ziv-aflibercept (0.67 (0.45) and 0.58 (0.43), respectively, based on previous research) [ 11 ]. G*power version 3.0.10 was used to calculate the difference between 2 paired readings using a 2-tailed t test with an α error = 0.05, a power = 80.0% and an effect size =0.65.…”

Results of Intravitreal Anti-VEGF Injection in Choroidal Neovascularizations Caused by Pathologies Other Than Age-Related Macular Degeneration

“…Case series reporting the results of ranibizumab (7,8,10,16), ziv-aflibercept (17), and bevacizumab (18) treatment for CNV unrelated to AMD have observed a ≥15 letter visual acuity gain rate of 36-57.1%. A <15 letter vision loss rate of 90.5-100% has been reported.…”

“…A <15 letter vision loss rate of 90.5-100% has been reported. Many studies in this area have reported a significant reduction in the CMT with anti-VEGF treatment (8,10,17,18). In a significant fraction of these studies, the patients had previously received other treatments for CNV or had received concurrent treatments during the study, which could affect treatment results.…”

“…In a significant fraction of these studies, the patients had previously received other treatments for CNV or had received concurrent treatments during the study, which could affect treatment results. In addition, the length of follow-up varies considerably between and within the studies, which is a handicap for comparisons (8,10,17,18).…”